- by sedlv
- September 3 2024
Scilex’s Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect
(September 3, 2024) | By Zoey Becker.
Semnur Pharmaceuticals, which is working on a non-opioid prospect for sciatica, has agreed to merge with special purpose acquisition company Denali Capital Acquisition Corp. in a deal worth $2.5 billion.
Upon closure of the deal, which is expected by the first quarter of 2025, Semnur plans to continue the road to potential commercialization for its lead candidate Semdexa.
Semdexa is an injectable corticosteroid gel formulation of dexamethasone sodium phosphate that’s meant to treat patients with moderate to severe lumbosacral radicular pain, or sciatica.